Laid off from Sutro Biopharma.

What Sutro Biopharma layoffs have meant for employees

Luvelta, the antibody-drug conjugate Sutro had been testing in ovarian cancer, was shelved in March 2025, though Sutro had promoted early phase 2/3 results in December 2024. Truist analysts wrote that the decision looked driven mainly by the need to conserve capital, since no partner had signed on, BioSpace reported, and Sutro's new chief executive, Jane Chung, said the shift would bring a considerable reduction in operating costs. The luvelta work being wound down was principally clinical and manufacturing, the March 13 8-K said, and winding it down still took staff time, since the 10-K for 2025 counts direct employee costs in moving patients from company-led trials to standard care or, in limited cases, post-trial access. Once Sutro had handed production of cell-free extract and custom reagents to contract manufacturers, it was relying on an external manufacturing strategy, as its mid-2026 10-Q puts it, and making none of those materials itself, which is why the San Carlos plant could wind down.

September's cut was explained in terms of runway. After March, the savings were expected to carry Sutro into the fourth quarter of 2026, BioSpace reported, and the September 29 8-K said the new restructuring, with some expected milestone payments, should extend that into at least mid-2027. This time the cut came out of the employees still at Sutro after luvelta was shelved, as the company prioritized its preclinical ADC programs and research collaborations; for anyone who had kept a job through the spring, the second cut came some six and a half months after the first. The gap between notice and effective date was also shorter the second time. California’s 2024-25 report lists an effective date of August 1 for the March notices, more than four months after they were dated, and the state’s 2025-26 report lists September 30 for the September ones, the next day. The September notices also named more jobs in San Carlos, where manufacturing went on until December.

Sutro's Severance and Change in Control Plan covers eligible U.S.-based employees at vice president and above. When an eligible vice president or senior vice president is let go other than during a change in control, the plan sets cash severance at 0.75 times base salary, paid in monthly installments that start after the 60th day following termination, plus a prorated bonus and up to nine months of company-paid COBRA. The separation agreement of the chief executive who left in March 2025 matched the plan's top tier in that same situation, 150% of his salary and as much as 18 months of COBRA, and Jane Chung, who succeeded him, stayed in the plan as a Tier 1 participant. If you're a participant offered payment under this plan and were handed its release, those payments depend on the release becoming effective by the 60th day after your last day, so consider putting that date on a calendar as soon as you have the papers. If the plan is paying your COBRA premiums, those payments stop once you're eligible for coverage under another employer's plan, so coverage through a new employer can end them early.

If your Sutro job was in California, you can check our page on California unemployment benefits. If your separation terms included company-paid health coverage, consider noting the month those payments end, because how COBRA works explains what the same coverage costs once an employer stops paying. If you received a California notice, you might keep it alongside your separation papers; the state's reports list each Sutro notice by its date and site. And if you're asked in an interview why your job ended, both 8-Ks describe corporate restructurings built around Sutro's drug pipeline, and explaining a layoff offers short ways to say so.